Eosinophils Target Therapy for Severe Asthma: Critical Points by Brussino, L. et al.
Review Article
Eosinophils Target Therapy for Severe Asthma: Critical Points
L. Brussino ,1,2 E. Heffler ,3,4 C. Bucca ,1,5 S. Nicola ,1 and G. Rolla1,2
1Department of Medical Science, University of Torino, Italy
2Allergy and Clinical Immunology Unit, AO Ordine Mauriziano Umberto I, Torino, Italy
3Personalized Medicine, Asthma and Allergy, Humanitas Research Hospital, Rozzano, Italy
4Department of Biomedical Sciences, Humanitas University, Rozzano, Italy
5Azienda Ospedaliero Universitaria Citta` della Salute e della Scienza, S.C. Pneumologia U, 10126 Torino, Italy
Correspondence should be addressed to L. Brussino; luisa.brussino@unito.it
Received 10 July 2018; Revised 24 September 2018; Accepted 17 October 2018; Published 25 October 2018
Academic Editor: Taiyoun Rhim
Copyright © 2018 L. Brussino et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Asthma is a chronic and heterogeneous disease, which is defined as severe disease whenever it requires treatment with a high dose
of inhaled corticosteroids plus a second controller and/or systemic corticosteroids to prevent it from becoming “uncontrolled”
or if it remains “uncontrolled” despite this therapy. Severe asthma is a heterogeneous condition consisting of phenotypes such as
eosinophilic asthma, which is characterized by sputum eosinophilia, associatedwith mild tomoderate increase in blood eosinophil
count, frequently adult-onset, and associated with chronic rhinosinusitis with nasal polyps in half of the cases. Eosinophilic
asthma is driven by T2 inflammation, characterized, among the others, by interleukin-5 production. IL-5 plays a key role in the
differentiation, survival,migration, and activation of eosinophils, and it has become an appealing therapeutic target for eosinophilic
asthma. In recent years two monoclonal antibodies (mepolizumab and reslizumab) directed against IL-5 and one monoclonal
antibody directed against the alpha-subunit of the IL-5 receptor (benralizumab) have been developed. All these IL-5 target drugs
have been shown to reduce the number of exacerbation in patients with severe asthma selected on the basis of peripheral blood
eosinophil count. There are still a number of unresolved issues related to the anti-IL5 strategy in eosinophilic asthma, which
are here reviewed. These issues include the effects of such therapy on airway obstruction and asthmatic symptoms, the level of
baseline eosinophils that predicts a response to treatment, the relationship between blood and airway eosinophilia, and, perhaps
most importantly, how to elucidate the pathogenetic role played by eosinophils in the individual patient with severe eosinophilic
asthma.
1. Introduction
Asthma is a chronic disease characterized by different clinical
presentations, comorbidities, and outcomes, affecting an
estimated 300 million people worldwide, of all ages, who
usually need many specialists in order to be well managed
[1–5]. Although asthma is generally mild and well controlled,
the severe form, which represents at most 10% of asthmatic
patients, can be refractory to conventional therapies, such as
inhaled corticosteroids (ICSs), inhaled bronchodilators, and
oral leukotriene modifiers [6, 7].
The outcome of asthma therapy becomes very important
in terms of public health, social impact, and quality of life,
particularly for those people suffering from severe asthma. It
is therefore becoming more and more important to identify
patients’ phenotypes and to target precisemolecules to obtain
a good asthma control.
2. Asthma Phenotypes and Endotypes
Asthma can be classified into different phenotypes, according
to its clinical presentation, concomitant comorbidities such
as nasal polyposis or obesity, identifiable triggers, including
allergen or aspirin sensitivity and response to therapy. Phe-
notypes, asmeasurable and observable features of asthma, are
also available in defining eosinophilic and noneosinophilic
asthma. In fact, the lack of knowledge of pathogenesis
underlying each different phenotype represents a limit in
understanding the mechanisms of Asthma subgroups and
in disease management. Recently it has been proposed that
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the definition of endotype represents a specific biological
mechanism which underlies a given phenotype.
The identification of different endotypes provides a con-
tribution to lead novel treatments, such as biologic therapies
to target specific inflammatory mediators (e.g., IL-5) [8, 9].
The two-main recognized asthma endotypes are based
on high or low T-helper 2 (TH2) cell airway inflammation.
Considering also type 2 innate lymphoid cells (ILC2), which
are outside the originally described Th2 cell population
but producing the same cytokines, (T2)-high or (T2)-low
has emerged as a more appropriate and inclusive term for
defining asthma endotypes.
The pathophysiology of T2 low asthma is not completely
understood, but it is thought that it could be characterized
by neutrophilic inflammation, suggesting a TH1 and/or TH17
cells activation.
On the other hand, in T2 high asthma, overproduction of
eosinophils, driven by an overproduction of type 2 cytokines
from T-helper 2 and innate lymphoid cells, is commonly
found in many patients, and it correlates with more severe
disease, with airway dysfunction [10].
3. Eosinophilic Asthma and IL5
In more than 50% of patients affected by severe eosinophilic
asthma (SEA), both blood and sputum eosinophilia are
associated with worse disease control and prognosis [11]. In
addition, blood eosinophilia often reflects asthma severity
[12] and the relationship between the reduction in sputum
eosinophils and the reduction of exacerbations after ICS
therapy is well recognized [13].
Interleukin 5 (IL-5) is a cytokine produced by limited
types of cells, such as CD4+ T cells, innate lymphocytes
type 2 (ILC-2), mast cells, and eosinophils, which are all
involved in the airway inflammation of asthma. Whatever
the source, IL-5 plays a major role in the differentiation,
survival, migration, and activation of eosinophils. This is the
reason why IL-5 represents an appealing therapeutic target
for hypereosinophilic conditions.
4. Anti-IL5 Strategy in Eosinophilic Asthma
At the beginning of 2000s, the therapeutic role of IL-5
antagonists in asthma was postulated following the obser-
vation in rats of the eosinophils reduction in BAL and
lung tissue and reduction of airway hyperresponsiveness
after treatment with anti-IL5 monoclonal Antibodies (mAbs)
intranasally, intravenously, or intraperitoneally, suggesting a
good outcome also in treatment of human asthma [14].
Leckie et al. analyzed the effects of mepolizumab, an anti-
IL5 monoclonal antibody, in 24 patients with mild asthma,
observing a reduction of eosinophils in sputum and blood
after allergen challenge, but they did not find a decrease in
airway hyperresponsiveness to histamine or in late reaction
after allergen challenge [15]. A few years later, it was observed
that mepolizumab induced reduction in blood eosinophilia
and a slight improvement in FEV1 in asthmatic patients
taking high doses of ICS and/or oral corticosteroids, without
significant changes in other clinical outcomes [16].
The efficacy ofmepolizumab in patients with eosinophilic
asthma has been preliminary reported in in 2009 in 2
randomized double-blind, placebo controlled studies. In the
first one,Haldar demonstrated the reduction of exacerbations
and the improvement in AQLQ scores in 29 patients with
refractory eosinophilic asthma. The second study by Nair
and Coll reported the reduction of eosinophils in blood and
sputum, as well as prednisone sparing in 9 patients who had
asthma with sputum eosinophilia despite prednisone treat-
ment. In both studies patients received 750 mg intravenously
of mepolizumab for 12 and 5 months, respectively [17, 18].
Later, in 2012 another study reported the efficacy of
mepolizumab in a group of patients affected by eosinophilic
asthma [19]. These observations placed the basis for the
selection of patients based on the disease phenotype to
achieve a tailored therapy. Furthermore, the knowledge of
eosinophils involvement in asthma and the potential to block
IL-5 stimulated other research studies to better identify the
field of application of the new anti-IL5 mAbs [20].
In the last two years two similar biologics therapies
targeting IL-5, mepolizumab and reslizumab, have been
approved, as well as anti-IL-5 alpha receptor, benralizumab.
These agents can be used as add-on therapy in subjects with
an eosinophilic asthma phenotype, poorly controlled with
standard therapy. Mepolizumab and reslizumab both target
and bind to IL-5 directly, whereas benralizumab targets the
IL-5 receptor alpha subunit. [21, 22].
The primary outcome in mepolizumab registration stud-
ies was the reduction of annual frequency of significant
asthma exacerbations, which was defined as worsening of
asthma which needed to be treated with systemic gluco-
corticoids for at least 3 days or when the patient visited
an emergency department or was hospitalized. Secondary
endpoints were the effects of treatment on blood eosinophil
counts, asthma control evaluated by ACQ-5 score, asthma-
related quality of life, and forced expiratory volume in 1 s
(FEV1) [19]. Due to the hierarchical gatekeeping in the study
design, the secondary endpoints were not analyzed in the
registration study, not having reached the significant differ-
ence in reduction of exacerbation requiring ED admission
between iv mepolizumab and placebo [23].
On the other side, primary outcome for reslizumab
registration studies was the change from baseline in pre-
bronchodilator FEV1 over 16 weeks. Secondary endpoints
included ACQ scores, FVC, forced expiratory flow at 25%
to 75% of FVC (FEF25%-75%), patient-reported control of
asthma symptoms, short-acting 𝛽-agonist (SABA) use in the
three days before the visit, blood eosinophil levels, and safety
[24]. All the secondary endpoints were reached except for
ACQ, which did not show any difference between reslizumab
and placebo.
Lastly, the primary outcome in benralizumab registration
studies was annual exacerbation rate ratio versus placebo for
patients receiving high-dosage ICS plus LABA with baseline
blood eosinophils 300 cells per 𝜇L or greater (intention-
to-treat analysis), while secondary efficacy endpoints were
prebronchodilator FEV1 and total asthma symptom score
for patients receiving high-dose inhaled corticosteroids plus
LABA with baseline blood eosinophils 300 cells per 𝜇L or
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greater. Additional secondary endpoints were time to first
asthma exacerbation, annual rate of asthma exacerbations
associated with emergency department visit, urgent care visit,
or admission to hospital (defined as an admission to an
inpatient facility and/or evaluation and treatment in a health-
care facility for 24 hours or longer), postbronchodilator
FEV1, ACQ-6 score, and AQLQ(S)+12 score. The annual
rate of asthma exacerbations requiring an ED admission
did not differ between the benralizumab and placebo, and
benralizumab treatment did not alter the time to first asthma
exacerbation requiring an emergency department visit or
admission to hospital [25].
Analyzing the efficacy studies of the threeAnti-IL5mAbs,
it is important to focus on the primary outcome, which is,
for mepolizumab and benralizumab [19, 21], the reduction
in annual asthma exacerbation numbers and, limited to
reslizumab, the improvement in lung function test [24].
The study design for mepolizumab considered only
patients with at least two exacerbations in the last year,
showing a significant reduction rate in exacerbation of 53%
for the group receiving subcutaneousmepolizumab [19], with
an exacerbation rate of 0.93/year.
A secondary (post hoc) analysis of data from two ran-
domized, double-blind, placebo-controlled studies of at least
32 weeks duration, DREAM and MENSA, was performed to
evaluate the relationship between baseline eosinophil counts
and efficacy of Mepolizumab, stratifying patients by different
baseline eosinophil thresholds (count and ranges) in the
blood, specifically baseline ≥150, ≥300, ≥400, and ≥500 cells
per 𝜇L, and baseline blood eosinophil ranges (<150 cells per
𝜇L, ≥150 cells per 𝜇L to <300 cells per 𝜇L, ≥300 cells per 𝜇L
to <500 cells per 𝜇L, and ≥500 cells per 𝜇L).
It was observed that the exacerbation rate reduction with
mepolizumab versus placebo increased progressively from
52% in patients with a baseline peripheral eosinophil count of
at least 150 cells per𝜇L to 70% in thosewith a baseline count of
at least 500 cells per 𝜇L. When the baseline eosinophil count
was less than 150 cells per 𝜇L, the efficacy of mepolizumab
was clearly reduced [26].
5. Unresolved Issues Related to the Anti-IL5
Therapy in Eosinophilic Asthma
5.1. Annual Exacerbation Rate Reduction. One important
question is the clinical meaning of 50% reduction of annual
exacerbation rate and the primary outcome of mepolizumab
studies, in the patients who report just two exacerbation/year.
Even if exacerbation as defined in clinical trials is an
“all-or-nothing” parameter, it is well recognized that patients
with high symptom burden have more frequent exacerba-
tions. The decrease of annual exacerbations per se does not
automatically imply a comparable decrease of daily asthmatic
symptoms, even if a 50% decrease in asthmatic symptoms has
been reported in the same registration studies.
Other clinical endpoints, in addition to annual exacer-
bation rate, as the need of frequent oral corticosteroid use,
asthmatic symptoms and quality of life, should be taken into
account by clinicians who consider anti-IL-5 therapy for their
patients with severe asthma.
5.2. FeNO as a Marker of T2 Inflammation. Outcomes which
have been explored in secondary registration studies were
the reduction in blood eosinophil count, the improvement
in quality-of-life, the increase of forced expiratory flows,
and the reduction in using of SABA. Markers of tissue
eosinophilia which have been investigated in these studies
were the sputum eosinophilia and, in one study only, the
change of exhaled nitric oxide (FeNO) after mepolizumab
therapy.
FeNO measurement is esteemed to be particularly useful
to identify a high T2 state. The official ATS clinical practice
guideline recommends that high FeNO > 50 ppb in adults
and > 35 ppb in children can be used to indicate eosinophilic
inflammation [27] in subjects, not in steroid therapy.
However, in spite of the expected correlation between
the FeNO values and the number of eosinophils in the
sputum of patients with eosinophilic asthma, in clinical
setting a discrepancy is often observed between the two
aforementioned values: high FeNO values may be sometimes
observed in patients with normal sputum eosinophils count
and vice versa.
Mepolizumab has been shown to decrease consistently
blood and sputum eosinophil counts in patients with
eosinophilic asthma, with no effect on FeNO levels [17].
A possible explanation of the absence of efficacy of
mepolizumab on FeNO is that the molecular pathways that
lead to an increase in FeNO are different from those that
underlie the recruitment and activation of eosinophils, as
the FeNO is mainly related to the pathways involved in T2
mediated asthma, while peripheral eosinophilia in asthmatic
patients depends also upon the activity of lymphoid cells
(ILC2) type 2 [28].
Recent evidence shows indeed that, in atopic asthma, the
production of FeNO is stimulated by proinflammatory T2-
cytokines, other than IL-5, such as IL-4 and IL-13, making
NOabiomarker of T2-driven inflammation [29], which is not
susceptible to the action of the anti-IL5 mAbs [30].
5.3. Eosinophil Count for the Assessment of Anti-IL5 Efficacy.
Peripheral blood and sputum eosinophil counts have been
shown to be consistently decreased by anti-IL5 drugs in all
the three registration studies [23–25].
It is well known that both blood and pulmonary
eosinophils are increased in patients with eosinophilic
asthma. Whether peripheral blood eosinophils mirror
bronchial tissue eosinophilia is not known. Also how
important is the pathogenetic role played by eosinophils in
asthma is not completely known. Bronchial eosinophilia may
persist even when peripheral blood eosinophil count has
been reduced by anti-IL-5 treatment [31].
Even the reduction of bone-marrow eosinophils,
obtained by benralizumab treatment, was not able to
abolish eosinophils infiltration in bronchial biopsies [13] or
ECP levels in the sputum [32]. This observation suggests the
important role of local mechanisms and/or of other cytokines
in promoting eosinophils priming, recruitment, activation,
and survival in the tissues. Nevertheless, as the source of
eosinophil in the tissue is from the blood it is conceivable as
a cumulative benefit on tissue eosinofil level with persistent
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blockade of blood eosinophils, but the duration of blockade
required for measurable benefit on tissue eosinophils has not
been evaluated.
The best predictor of response to ICS/OCS in patients
with airway diseases, not only asthma, but also COPD and
chronic cough of eosinophilic bronchitis, is the presence of
eosinophils into the bronchial tissue, which is also predictive
of response to therapies that indirectly target eosinophils such
as anti-(IL-5) monoclonal antibodies [33, 34].Whether blood
or sputum eosinophils levels are the best predictor of therapy
response need to be assessed in specific studies.
Any asthma therapy which had eosinophils as target
will be much more effective the more it decreases airway
eosinophils and the more airway eosinophils are primary
players of airway inflammation. Unfortunately, markers of
airways eosinophils activation are not currently available,
and this is probably a great limitation to identify the
asthmatic patients who could benefit more from anti-IL5
therapies.
Free eosinophil granules (FEGs), released after
eosinophils’ lysis, are detectable in sputum of patients
with uncontrolled and severe asthma and the measure of
sputum FEGs could be a new marker of eosinophilic airway
inflammation [35].
FEGs contain toxic proteins which are responsible for
bronchial epithelial damage, and their presence in the sputum
is the consequence of eosinophils degranulation, which
is an important mechanism of tissue damage driven by
eosinophils [33, 36]. Moreover, the release of eosinophils’
peroxidase (EPX) has been related to local airway autoim-
munity, following the production of anti-EPX antibodies.
This autoimmune mechanism has been related not only
to failure of mepolizumab therapy but even to wors-
ening of asthma control in some patients with severe
eosinophilic asthma [37, 38] who receive the standard dose
of mepolizumab (100 mg s.c.). The same patients had been
shown to respond to higher dose or to i.v. reslizumab
[18, 23].
It has been suggested that lower doses of anti-IL-5 drugs
might not neutralize completely IL-5, which could still be
able to promote local airway eosinophilia, in spite of the
normalization of the blood eosinophil count [39, 40].
Another possibility is that a lower dose of anti-IL5 Mab
could drive airway eosinophilia through the production of
immune-complex and/or complement activation [38]. Such
immune complexes could act as depot of IL5, leading to an
increase in biological activity of the bound IL-5 [41]. This is
a theoretical risk that has not been corroborated by clinical
studies.
It has been recently demonstrated [42] that levels of Ig-
bound IL-5 in the sputum of mepolizumab nonresponder
patients was associated with increase in sputum eosinophils
count.
In conclusion, anti-IL-5 treatment is a novel therapeu-
tic strategy which may offer many clinical benefits to an
asthmatic patients, selected on the basis of recurrent asth-
matic exacerbation due to eosinophilic airway inflammation.
Certainly, such a strategy is not an option for patients
suffering from moderate persistent asthma, particularly if
they do not need frequent oral corticosteroid courses to
obtain asthma control. On the other hand, patients who,
despite receiving systemic glucocorticoids, had peripheral
blood eosinophil count well above 150 cells/mcL and frequent
asthma exacerbations would experience better control of
asthma symptoms along with reduced exacerbation rates [23,
43, 44].
Furthermore, the glucocorticoid-sparing effect of anti-
IL-5 therapy [44] may prevent the serious, often irreversible
adverse effects of glucocorticoids.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
References
[1] J. Corren, “Asthma phenotypes and endotypes: an evolving
paradigm for classification,” Discovery Medicine, vol. 15, no. 83,
pp. 243–249, 2013.
[2] A. Agusti, E. Bel, M. Thomas et al., “Treatable traits: toward
precision medicine of chronic airway diseases,” European Res-
piratory Journal, vol. 47, no. 2, pp. 410–419, 2016.
[3] K. F. Chung, “Targeting the interleukin pathway in the treat-
ment of asthma,”e Lancet, vol. 386, no. 9998, pp. 1086–1096,
2015.
[4] K. F. Chung, S. E. Wenzel, and J. L. Brozek, “International
ERS/ATS guidelines on definition, evaluation and treatment of
severe asthma,” European Respiratory Journal, vol. 43, pp. 343–
373, 2014.
[5] M. Masoli, D. Fabian, S. Holt, and R. Beasley, “The global bur-
den of asthma: executive summary of the GINA Dissemination
Committee Report,” Allergy: European Journal of Allergy and
Clinical Immunology, vol. 59, no. 5, pp. 469–478, 2004.
[6] P. J. Barnes and I. M. Adcock, “Glucocorticoid resistance in
inflammatory diseases,”e Lancet, vol. 373, no. 9678, pp. 1905–
1917, 2009.
[7] A. N. Pepper, H. Renz, T. B. Casale, and H. Garn, “Biologic
Therapy and Novel Molecular Targets of Severe Asthma,” e
Journal of Allergy and Clinical Immunology: In Practice, vol. 5,
no. 4, pp. 909–916, 2017.
[8] J. Lo¨tvall, C. A. Akdis, L. B. Bacharier et al., “Asthma endotypes:
a new approach to classification of disease entities within
the asthma syndrome,” e Journal of Allergy and Clinical
Immunology, vol. 127, no. 2, pp. 355–360, 2011.
[9] T. F. Carr, A. A. Zeki, and M. Kraft, “Eosinophilic and
noneosinophilic asthma,” American Journal of Respiratory and
Critical Care Medicine, vol. 197, no. 1, pp. 22–37, 2018.
[10] J. Jared Darveaux andW. W. Busse, “Biologics in Asthma –The
Next Step Towards Personalized Treatment,” Journal of Allergy
and Clinical Immunology: In Practice, vol. 3, no. 2, pp. 152–161,
2015.
[11] R. Buhl, M. Humbert, L. Bjermer et al., “Severe eosinophilic
asthma: a roadmap to consensus,”EuropeanRespiratory Journal,
vol. 49, Article ID 1700634, 2017.
[12] W. Busse, S. Spector, K. Rose´n, Y. Wang, and O. Alpan, “High
eosinophil count: A potential biomarker for assessing successful
omalizumab treatment effects,” e Journal of Allergy and
Clinical Immunology, vol. 132, no. 2, pp. 485-486, 2013.
BioMed Research International 5
[13] M. Laviolette, D. L. Gossage, G. Gauvreau et al., “Effects
of benralizumab on airway eosinophils in asthmatic patients
with sputum eosinophilia,” e Journal of Allergy and Clinical
Immunology, vol. 132, no. 5, pp. 1086–1096, 2013.
[14] F. R. Shardonofsky, J. Venzor III, R. Barrios, K.-P. Leong, and
D. P. Huston, “Therapeutic efficacy of an anti-IL-5 monoclonal
antibody delivered into the respiratory tract in a murine model
of asthma,”e Journal of Allergy and Clinical Immunology, vol.
104, no. 1, pp. 215–221, 1999.
[15] M. J. Leckie, A. Ten Brinke, J. Khan et al., “Effects of an
interleukin-5 blocking monoclonal antibody on eosinophils,
airway hyper-responsiveness, and the late asthmatic response,”
e Lancet, vol. 356, pp. 2144–2148, 2000.
[16] J. C. Kips, B. J. O’Connor, S. J. Langley et al., “Effect of
SCH55700, a humanized anti-human interleukin-5 antibody, in
severe persistent asthma: A pilot study,” American Journal of
Respiratory and Critical CareMedicine, vol. 167, no. 12, pp. 1655–
1659, 2003.
[17] P. Haldar, C. E. Brightling, B. Hargadon et al., “Mepolizumab
and exacerbations of refractory eosinophilic asthma,” e New
England Journal of Medicine, vol. 360, no. 10, pp. 973–984, 2009.
[18] P.Nair,M.M.M. Pizzichini,M.Kjarsgaard et al., “Mepolizumab
for prednisone-dependent asthma with sputum eosinophilia,”
e New England Journal of Medicine, vol. 360, no. 10, pp. 985–
993, 2009.
[19] P. Nair, “Anti-interleukin-5monoclonal antibody to treat severe
eosinophilic asthma,”eNewEngland Journal of Medicine, vol.
371, no. 13, pp. 1249–1251, 2014.
[20] P. Flood-Page, C. Swenson, I. Faiferman et al., “A study to
evaluate safety and efficacy of mepolizumab in patients with
moderate persistent asthma,” American Journal of Respiratory
and Critical Care Medicine, vol. 176, no. 11, pp. 1062–1071, 2007.
[21] M. Khorasanizadeh, M. Eskian, A. H. Assa’ad, C. A. Camargo
Jr., and N. Rezaei, “Efficacy and Safety of Benralizumab, aMon-
oclonal Antibody against IL-5R𝛼, in Uncontrolled Eosinophilic
Asthma,” International Reviews of Immunology, vol. 35, no. 4,
pp. 294–311, 2016.
[22] M. P. Giannetti and J. C. Cardet, “Interleukin-5 antagonists
usher in a new generation of asthma therapy,” Current Allergy
and Asthma Reports, vol. 16, no. 11, article 80, 2016.
[23] H. G. Ortega, M. C. Liu, and I. D. Pavord, “Mepolizumab
treatment in patients with severe eosinophilic asthma,”eNew
England Journal of Medicine, vol. 371, no. 13, pp. 1198–1207, 2014.
[24] L. Bjermer, C. Lemiere, J. Maspero, S. Weiss, J. Zangrilli, andM.
Germinaro, “Reslizumab for Inadequately Controlled Asthma
With Elevated Blood Eosinophil Levels: A Randomized Phase 3
Study,” CHEST, vol. 150, no. 4, pp. 789–798, 2016.
[25] J. M. FitzGerald, E. R. Bleecker, P. Nair et al., “Benralizumab, an
anti-interleukin-5 receptor 𝛼 monoclonal antibody, as add-on
treatment for patients with severe, uncontrolled, eosinophilic
asthma (CALIMA): a randomised, double-blind, placebo-
controlled phase 3 trial,” e Lancet, vol. 388, no. 10056, pp.
2128–2141, 2016.
[26] H. G. Ortega, S. W. Yancey, B. Mayer et al., “Severe eosinophilic
asthma treated with mepolizumab stratified by baseline
eosinophil thresholds: a secondary analysis of the DREAM and
MENSA studies,”e Lancet Respiratory Medicine, vol. 4, no. 7,
pp. 549–556, 2016.
[27] R. A. Dweik, P. B. Boggs, S. C. Erzurum et al., “An official ATS
clinical practice guideline: interpretationof exhaled nitric oxide
levels (FENO) for clinical applications,” American Journal of
Respiratory and Critical Care Medicine, vol. 184, no. 5, pp. 602–
615, 2011.
[28] H. Coumou and E. H. Bel, “Improving the diagnosis of
eosinophilic asthma,” Expert Review of Respiratory Medicine,
vol. 10, no. 10, pp. 1093–1103, 2016.
[29] L. Bjermer, K. Alving, Z. Diamant et al., “Current evidence and
future research needs for FeNO measurement in respiratory
diseases,”RespiratoryMedicine, vol. 108, no. 6, pp. 830–841, 2014.
[30] A. Crespo, J. Giner, M. Torrejo´n et al., “Clinical and inflam-
matory features of asthma with dissociation between fractional
exhaled nitric oxide and eosinophils in induced sputum,”
Journal of Asthma & Allergy Educators, vol. 53, no. 5, pp. 459–
464, 2016.
[31] E. Papathanassiou, S. Loukides, and P. Bakakos, “Severe asthma:
anti-IgE or anti-IL-5?” European Clinical Respiratory Journal,
vol. 3, no. 1, Article ID 31813, 2016.
[32] W. W. Busse, R. Katial, D. Gossage et al., “Safety profile,
pharmacokinetics, and biologic activity of MEDI-563, an anti-
IL-5 receptor𝛼 antibody, in a phase I study of subjectswithmild
asthma,” e Journal of Allergy and Clinical Immunology, vol.
125, no. 6, pp. 1237–1244, 2010.
[33] P. Nair, S. I. Ochkur, C. Protheroe et al., “Eosinophil per-
oxidase in sputum represents a unique biomarker of airway
eosinophilia,” Allergy: European Journal of Allergy and Clinical
Immunology, vol. 68, no. 9, pp. 1177–1184, 2013.
[34] M. Mukherjee, R. Sehmi, and P. Nair, “Anti-IL5 therapy for
asthma and beyond,” World Allergy Organization Journal, vol.
7, no. 1, article 32, 2014.
[35] C. Persson, “Primary lysis of eosinophils in severe desquamative
asthma,”Clinical & Experimental Allergy, vol. 44, no. 2, pp. 173–
183, 2014.
[36] M. Mukherjee and P. Nair, “Blood or sputum eosinophils to
guide asthma therapy?” e Lancet Respiratory Medicine, vol.
3, no. 11, pp. 824-825, 2015.
[37] M. Mukherjee, D. C. Bulir, K. Radford et al., “Sputum autoanti-
bodies in patients with severe eosinophilic asthma,”e Journal
ofAllergy andClinical Immunology, vol. 141, no. 4, pp. 1269–1279,
2018.
[38] J. Takiguchi, H. Ohira, T. Rai, K. Abe, A. Takahashi, and Y. Sato,
“Anti-eosinophil peroxidase antibodies detected in patients
with primary biliary cirrhosis,”Hepatology Research, vol. 32, no.
1, pp. 33–37, 2005.
[39] S. G. Smith, R. Chen, M. Kjarsgaard et al., “Increased numbers
of activated group 2 innate lymphoid cells in the airways of
patients with severe asthma and persistent airway eosinophilia,”
e Journal of Allergy and Clinical Immunology, vol. 137, no. 1,
pp. 75.e8–86.e8, 2016.
[40] R. Sehmi, S. G. Smith, M. Kjarsgaard et al., “Role of local
eosinophilopoietic processes in the development of airway
eosinophilia in prednisone-dependent severe asthma,” Clinical
& Experimental Allergy, vol. 46, no. 6, pp. 793–802, 2016.
[41] M.Mukherjee,H. F. Lim, S.Thomas et al., “Airway autoimmune
responses in severe eosinophilic asthma following low-dose
Mepolizumab therapy,”Allergy, Asthma&Clinical Immunology,
vol. 13, no. 1, 2017.
[42] M. Mukherjee, F. A. Paramo, M. Kjarsgaard et al., “Weight-
adjusted intravenous reslizumab in severe asthma with inad-
equate response to fixed-dose subcutaneous mepolizumab,”
American Journal of Respiratory and Critical CareMedicine, vol.
197, no. 1, pp. 38–46, 2018.
6 BioMed Research International
[43] P. Haldar, C. E. Brightling, A. Singapuri et al., “Outcomes
after cessation of mepolizumab therapy in severe eosinophilic
asthma: A 12-month follow-up analysis,” e Journal of Allergy
and Clinical Immunology, vol. 133, no. 3, pp. 921–923, 2014.
[44] E. H. Bel, S. E. Wenzel, P. J. Thompson et al., “Oral
glucocorticoid-sparing effect of mepolizumab in eosinophilic

















































































Submit your manuscripts at
www.hindawi.com
